Table 2. Resistance patterns of the 25 sequences with nucleoside reverse transcriptase inhibitor (NRTI) mutations analyzed on the Stanford HIV database.
| Mutational patterns | Drug resistance profile | |||||||
|---|---|---|---|---|---|---|---|---|
| No (%) | &3TC | ¢FTC | šABC | ¶ AZT | ¥d4T | μddL | +TDF | |
| ART-Experienced (n = 21) | ||||||||
| D67N-M41L-M184V-L210W-T215F/Y | 1 (4.0) | *HLR | HLR | HLR | HLR | HLR | HLR | IR |
| D67N-K70R-M184V-T215Y-K219E/Q | 1 (4.0) | HLR | HLR | IR | HLR | HLR | IR | øLLR |
| M184V-L210W-T215Y | 1 (4.0) | HLR | HLR | IR | HLR | HLR | IR | LLR |
| A62V-K65R-V75A/I/T-M184V | 1 (4.0) | HLR | HLR | HLR | S | HLR | HLR | †IR |
| Q151M-M184V | 1 (4.0) | HLR | HLR | HLR | IR | IR | HLR | #S |
| M184V-T215F | 1 (4.0) | HLR | HLR | IR | IR | IR | LLR | S |
| K70R-M184V | 1 (4.0) | HLR | HLR | LLR | LLR | S | ‡PLR | S |
| T69SEA/SES-M184V-T215Y | 1 (4.0) | HLR | HLR | IR | IR | IR | LLR | S |
| K70R-M184V-T69N | 2 (8.0) | HLR | HLR | LLR | LLR | PLR | LLR | S |
| M184V | 8 (32.0) | HLR | HLR | LLR | S | S | PLR | S |
| V118I, K219ER | 1 (4.0) | S | S | PLR | LLR | LLR | PLR | S |
| M41L | 1 (4.0) | S | S | S | LLR | LLR | S | S |
| T69N | 1 (4.0) | S | S | S | S | S | PLR | S |
| ART-Naïve (n = 4) | ||||||||
| M184V-T215F | 1 (4.0) | HLR | HLR | IR | IR | IR | LLR | S |
| M184V | 1 (4.0) | HLR | HLR | LLR | S | S | PLR | S |
| T69N | 1 (4.0) | S | S | S | S | S | PLR | S |
| E44D | 1 (4.0) | S | S | S | S | S | S | S |
&3TC: Lamivudine
šABC: Abacavir
¶ AZT: Zidovudine
¥d4T: Stavudine
μddl: Didanosine
¢FTC: Emtricitabine
+TDF: Tenofovir
*HLR: high-level resistance
øLLR: Low-level resistance
†IR: intermediate resistance
‡PLR: Potential Low-level resistance
#S: susceptible.